members of the Salvarsan Committee of the British Medical Research Council that some of the brands of " 9I4" then in use for the treatment of syphilis did not appear to be affording the clinical results which experience had led them to expect of such compounds. The observations of Burn, Durham and Marchal on the effect of the compounds in question on mice infected with trypanosomes and those of Mills on their effect in causing the disappearance of Sp. pallida from the secretion of early syphilitic lesions in man substantially supported the clinical impression as to their inferiority from the point of view of therapeutic potency. The manufacturers of the brands in question immediately took steps to remove the defects revealed by this investigation, and it can fairly be said now that their products are equal to any other in respect of power to bring about the disappearance of Sp. pallida from the secretion of early syphilitic lesions. This experience was thus distinctive in two respects. (i) It appeared to establish a rough parallelism between the trypanocidal activity of an arsphenamine preparation and its ability to bring about the disappearance of Sp. pallida from the secretion of early syphilitic lesions; it appeared to show also that a preparation that was indifferent in these two respects would afford indifferent clinical results. (2) It afforded an example of the practical value of a test of therapeutic potency, since here it at once brought about abandonment of certain manufacturing processes which were resulting in products of low toxicity, but (a fact hitherto unsuspected by the manufacturers) of comparatively low therapeutic power. insure against undue toxicity or to test therapeutic potency, but presumably its object is the former, since no test dose is specified, and in the German tests 5 it is laid down that each batch after being subjected to various tests on animals shall be tried clinically for certain toxic effects.
I am not closely acquainted with the actual practice in countries other than Great Britain with regard to tests applied to arsphenamine preparations before sale to the public, but believe that in a number of them, although a toxicity test may be compulsory, a test of therapeutic potency is applied far less frequently; also that, as a rule, when a therapeutic test is applied it is only the trypanocidal power which is investigated. It might be thought that a test of minimum toxicity would guard against the sale of products of inferior therapeutic potency, but it has been shown that there is no reliable parallelism between toxicity and therapeutic potency. Thus Durham, Gaddum and Marchal 6 found that a certain brand of " 9I4 " was more toxic than the standard preparation, but therapeutically much less potent.
Schamberg and Kolmer, with Madden,7 in a paper advocating the imposition of a therapeutic test, showed in i8 samples of " 9I4 " from seven different makers a fairly uniform maximum tolerated dose (0.20 to o-30 gm. per kgm.), but minimum trypanocidal doses, ranging from 0o004 to more than o-oI2 gm. per kgm. of body weight. The lack of parallelism between toxicity and trypanocidal activity is also brought out in a recent paper by Rothermundt. The inevitable conclusion from the evidence so far presented is that a test of toxicity is not sufficient; it should be supplemented by one of therapeutic potency. The question then arises if a test of trypanocidal activity is a sufficient guide to therapeutic potency vis-a-vis Sp. pallida. The reports of Dale and White, of Voegtlin and Miller, and of Schamberg, Kolmer and Raiziss suggested a parallelism which was generally close enough for practical purposes, and this opinion was definitely offered in the paper by Schamberg and Kolmer, with Madden, though here the trypanocidal and spirochaeticidal results were not parallel in 4 out of the i8 samples that were tested. In the paper by Rothermundt already mentioned it appears to have been assumed that brands of " 9I4 " can be compared in respect of therapeutic efficacy by the measure of their trypanocidal activity. On the other hand, Probey and McCoy 9 found that two brands of neoarsphenamine differing strongly in trypanocidal activity ( It appears, therefore, that although trypanocidal activity of an arsphenamine preparation may be a rough guide to its spirochaeticidal power, it is safer to test this also. The spirochaeticidal power could be tested on rabbit syphilis, as was done by Castelli and by Probey and McCoy, but a method that is more practicable for the clinician is to test the effect of a given dose of the remedy in question for its power to bring about the disappearance of Sp. pallida from the secretion of early syphilitic lesions within a given time. This is the method which was employed in the investigation reported by Dale and White and has been applied in clinics under my control for a number of years. Whenever the therapeutic efficacy of a given arsphenamine preparation has been in question a certain number of male adult patients suffering from primary syphilitic chancres, or from secondary lesions, in the serum of which Sp. pallida could be demonstrated easily received each a certain dose of the preparation, and twenty-four hours later the secretion was searched again for Sp. pallida. If these organisms were still present, the examination was repeated twenty-four hours later, sometimes after a further dose had been given. The results of a number of tests of various preparations that have been carried out on these lines by the staff of the V.D. Department, St. Thomas's Hospital, are shown in the following tables.
In all but one (Solusalvarsan 6 c.c.) of these series the remedy was given intravenously.
The table shows that, when administered by the intravenous route, the three types, arsphenamine diglucoside, sulpharsphenamine and solusalvarsan are at any rate less rapid in action than is almost any brand of neoarsphenamine. Sulpharsphenamine is usually regarded as intended for use by the intramuscular route, and the results of these tests are included in the present series only to show its inferiority to neoarsphenamine when given intravenously. The term inferiority is used advisedly in this connection because there is no reason to suppose that after intravenous injection the slowness of action of sulpharsphenamine is compensated for by its being retained in the body longer than is neoarsphenamine. Whether or not the slowness of action of arsphenamine diglucoside and of solusalvarsan is compensated for in this way I am unable to say. The results with the former of these two types show that those who use it must reckon with the fact that Sp. pallida continues an active existence for longer under it than under treatment with corresponding doses of neoarsphenamine, or (as I know from similar experiments 244 With regard to neoarsphenamine, although most of the brands that were tested gave satisfactory results, the performance of others shows the advisability of the clinician periodically testing for himself the therapeutic efficacy of the arsphenamine preparations he is in the habit of using for the treatment of syphilis. The results of these tests may perhaps also cause some workers to reflect on the effect (or lack of such) of a smaller dose 245 than o045 gm. neoarsphenamine (a rapidly excreted remedy) on the spirochaetal population in an adult man of average weight suffering from early syphilis. SUMMARY (i) Investigations by numerous workers have shown that different brands, and batches of those brands, of arsphenamine preparations can differ widely not only in toxicity but in therapeutic potency as judged by trypanocidal tests.
(2) Toxicity and therapeutic potency are not parallel, so that a test of minimum toxicity is not a safeguard against inferior therapeutic efficacy. 
